Interleukin 23: Pathogenetic Involvement and Therapeutic Target for Ulcerative Colitis
Journal of Clinical Medicine · 28.06.2025 · 14 (13) · 4590
DOI: 10.3390/jcm14134590 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 28.06.2025. Verfasst von Laura Parisio und 8 weiteren Autor:innen. Beteiligte Einrichtung: UOS Gastroenterologia, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Interleukin-23 (IL-23) is a key cytokine involved in the pathogenesis of various immuno-mediated inflammatory diseases. In recent years, several drugs selectively targeting IL-23 have been developed and three of them (mirikizumab, risankizumab and guselkumab) were successfully investigated in clinical trials for ulcerative colitis (UC). All of them showed a good profile for efficacy, alleviating symptoms, and inducing endoscopic and histologic improvement, with very low incidence of adverse events. Bowel urgency also emerged as a crucial outcome from patients’ perspective in the mirikizumab trials. The correct positioning of IL-23 inhibitors in the therapeutic algorithm for UC represents a new challenge for physicians, especially because it is not guided by biomarkers or predictors of effectiveness. Moreover, no comparative clinical data exist among the available IL-23 inhibitors, although molecular differences might potentially impact their effectiveness. A role for IL-23-inhibitors may also lie in combination with drugs with different mechanisms of action for complex, multi-refractory patients. This review, focusing on UC, summarizes all the clinical data available on IL-23 inhibitors and provides a perspective on the best clinical scenarios to maximize their effectiveness.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UOS Gastroenterologia, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy.
- Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
- Health Sciences Department, Magna Graecia University, 88100 Catanzaro, Italy.
- Department of Biomedical Sciences, Humanitas University, via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy.
- UOC Pronto Soccorso, Medicina d'Urgenza e Medicina Interna, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy.
- IBD UNIT-CEMAD (Centro Malattie Apparato Digerente), Medicina Interna e Gastroenterologia, Fondazione Policlinico A. Gemelli IRCCS, 00168 Rome, Italy.
ORCID-Profile: Giuseppe Cuccia, Federico Carrabetta, Luigi Carbone, Rocco Spagnuolo
Zitieren
APA
Parisio, L., Cuccia, G., Giudice, A., Carrabetta, F., Del Gaudio, A., Privitera, G., Carbone, L., Spagnuolo, R., & Pugliese, D. (2025). Interleukin 23: Pathogenetic Involvement and Therapeutic Target for Ulcerative Colitis. Journal of Clinical Medicine, 14(13), 4590. https://doi.org/10.3390/jcm14134590
Vancouver
Parisio L, Cuccia G, Giudice A, Carrabetta F, Del Gaudio A, Privitera G, et al. Interleukin 23: Pathogenetic Involvement and Therapeutic Target for Ulcerative Colitis. Journal of Clinical Medicine. 2025;14(13):4590. doi:10.3390/jcm14134590
BibTeX
@article{Parisio2025,
author = {Parisio, Laura and Cuccia, Giuseppe and Giudice, Anna and Carrabetta, Federico and Del Gaudio, Angelo and Privitera, Giuseppe and Carbone, Luigi and Spagnuolo, Rocco and Pugliese, Daniela},
title = {Interleukin 23: Pathogenetic Involvement and Therapeutic Target for Ulcerative Colitis},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {13},
pages = {4590},
doi = {10.3390/jcm14134590}
}
EUVIMED